Oct 11, 2016 Cellectar Biosciences To Present at SeeThru Equity and Dawson James Investor Conferences Learn More
Oct 6, 2016 Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma Learn More
Oct 4, 2016 Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603 Learn More